

ONE HUNDRED EIGHTEENTH CONGRESS

**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-3641  
Minority (202) 225-2927

August 9, 2023

Dr. Natalia Rost, M.D.  
President Elect  
American Academy of Neurology  
25 Massachusetts Avenue, Suite 500J  
Washington, DC 20001

Dear Dr. Rost:

Thank you for appearing before the Subcommittee on Health on Tuesday, July 18, 2023, to testify at the hearing entitled “Innovation Saves Lives: Evaluating Medicare Coverage Pathways for Innovative Drugs, Medical Devices, and Technology”.

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on Wednesday, August 23, 2023. Your responses should be mailed to Jolie Brochin, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [Jolie.Brochin@mail.house.gov](mailto:Jolie.Brochin@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Brett Guthrie  
Chair  
Subcommittee on Health

cc: Anna Eshoo, Ranking Member, Subcommittee on Health

**The Honorable Robert E. Latta**

- 1) While there is a clear need to innovate to dramatically slow the progression and ultimately cure Alzheimer's disease, millions of people currently living with the disease cannot wait around for future disease modifying therapies. To bridge that gap, how can we encourage investments in innovation today to effectively treat symptoms of Alzheimer's, like aggression and exit-seeking, which severely impacts the quality of life for patients and caregivers?
- 2) How can Congress ensure seniors have access to new therapies that alleviate the devastating symptoms of this disease?

**The Honorable Dan Crenshaw**

- 1) To your knowledge, *before* restricting Medicare coverage of FDA-approved therapies and devices to participants in clinical trials and studies does, does CMS do any analysis of the potential impacts on access to rural or other underserved populations? If so, is that information publicly available?